An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions

Trial Profile

An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Hypoxia; Idiopathic pulmonary fibrosis; Sickle cell anaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Basecamp Study
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 23 Oct 2017 According to a company media release, Global Blood Therapeutics has announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). This decision is based on results from three proof-of-concept studies, including a Phase 1 study in healthy volunteers called Basecamp and two Phase 2a studies in patients with IPF called GBT440-006 and ZEPHYR.
    • 23 Oct 2017 Status changed from recruiting to discontinued according to a Global Blood Therapeutics media release.
    • 29 Sep 2017 Planned number of patients changed from 12 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top